Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Nanoparticle Uptake in Human Corneal Epithelial Cells
2026-09-10
The reference study systematically examines how PLGA nanoparticle size and surface chemistry influence uptake by human corneal epithelial cells. Its in vitro evidence identifies energy-dependent endocytosis, particularly macropinocytosis and caveolae-mediated entry, as key mechanisms and provides design principles for more effective topical ocular delivery.
-
Amikacin disulfate: Practical Assay Workflows
2026-09-10
Build reproducible amikacin disulfate workflows for ribosomal, protein-binding, and antibiotic resistance studies. This guide connects water-based reagent handling with orthogonal fluorescence, activity, and docking readouts inspired by recent lysozyme-complexation research.
-
AMG 487 Workflow for CXCR3 Signaling
2026-09-09
AMG 487 provides a practical way to separate CXCR3-dependent migration, calcium signaling, and macrophage-state effects. This workflow combines potency-guided dosing with orthogonal readouts to investigate the context-sensitive CXCL10–CXCR3–LAMP1 axis.
-
Inducing Right Ventricular-Like Cardiomyocytes
2026-09-09
Saito et al. developed a modified GiWi differentiation strategy that enriches anterior second heart field-like progenitors and produces right ventricular-like cardiomyocytes from human pluripotent stem cells. The resulting cells differed from left ventricular-like controls in chamber-associated gene expression, spontaneous contraction, calcium handling, and cell size, providing a more defined platform for right-sided cardiac disease modeling.
-
GS967: Mapping Late INa to Arrhythmia Mechanisms
2026-09-08
GS967 is a cardiac late sodium current inhibitor for connecting Nav1.5 regulation with repolarization, calcium handling, and arrhythmia phenotypes. This article presents an assay-selection framework that extends aging-heart findings into rigorous ventricular electrophysiology and stress-model workflows.
-
H2S Deficiency, ER Stress, and Diabetic Cardiomyopathy
2026-09-07
The reference study identifies reduced endogenous hydrogen sulfide production as a mechanistically relevant component of palmitate-associated cardiac lipotoxicity in diabetic cardiomyopathy. By combining patient samples, diabetic rats, and AC16 cardiomyocytes, it links diminished H2S availability with ER-stress-associated injury and shows that NaHS or 4-PBA can lessen several pathological readouts.
-
HotStart Universal qPCR Mix for Gene Expression
2026-09-07
HotStart Universal 2X Green qPCR Master Mix combines hot-start Taq polymerase, Green I detection, and a ROX reference dye for real-time PCR gene expression analysis. Its product-documented design supports reproducible DNA amplification monitoring, while melt curve analysis remains important for confirming specificity.
-
SP2509: Mechanism-Led Paths in AML Epigenetics
2026-09-05
SP2509 is a potent Lysine-specific demethylase 1 antagonist for mechanism-led acute myeloid leukemia research. This thought-leadership guide connects LSD1 target engagement with H3K4 methylation, apoptosis, differentiation, model selection, combination strategy, and translational decision-making while distinguishing preclinical promise from clinical evidence.
-
Carbenoxolone disodium: Practical No-Paper Guide
2026-09-04
Carbenoxolone disodium is a practical perturbation tool for studying 11β-hydroxysteroid dehydrogenase activity, glucocorticoid handling, and gap junction communication in cell- and tissue-based workflows. When directly matched paper evidence is unavailable, use the product dossier and a controlled pilot design; do not treat the compound as validated in vivo efficacy evidence or as a highly selective probe.
-
EZ Cap™ Cre mRNA (m1Ψ): A Delivery-Aware Guide
2026-09-04
Discover how EZ Cap™ Cre mRNA (m1Ψ) connects transient RNA expression with durable Cre-loxP outcomes. This delivery-aware guide translates mRNA chemistry and extrahepatic delivery research into better assay design and interpretation.
-
PTX3–TLR4/NF-κB Axis in Glucocorticoid ONFH
2026-09-04
This study identifies a protective pentraxin 3 (PTX3)–TLR4/NF-κB–FGF21 signaling axis in glucocorticoid-induced osteonecrosis of the femoral head. By integrating patient samples, cellular injury models, Ptx3-deficient mice, pathway blockade, and downstream rescue experiments, the authors connect impaired osteogenesis and apoptosis with a tractable molecular mechanism.
-
GS967 Cardiac Late Sodium Current Workflows
2026-09-03
GS967 supports mechanistic studies of late sodium influx across ventricular myocyte, isolated-heart, and aging models. Its potency, voltage-dependent activity, and minimal use-dependence make it useful for connecting electrophysiology with calcium handling, relaxation, and arrhythmia prevention research.
-
Cyclopamine: Hedgehog Signaling Inhibitor Workflow
2026-09-02
Learn how to use Cyclopamine as a Smoothened-directed Hedgehog signaling inhibitor across cancer, apoptosis, and developmental workflows. This practical guide connects dose planning, orthogonal assays, APOC1-focused thyroid cancer research, and troubleshooting for more interpretable results.
-
Octanoic Acid–Rich Nutrition in IBD
2026-09-02
The reference study identifies a mechanistic link between octanoic acid-rich enteral nutrition, PPARγ/STAT-1/STAT-6 signaling, and intestinal macrophage polarization in inflammatory bowel disease. Its combination of nutritional intervention, pathway perturbation, and macrophage-cell validation provides a useful preclinical framework for evaluating immunometabolic therapies.
-
Talabostat Mesylate (PT-100): DPP4 and FAP Research
2026-09-01
Talabostat mesylate, also known as PT-100, is an orally active research inhibitor of DPP4 and FAP. Available evidence supports biochemical, cellular, and exploratory tumor-model studies, but the reported in vivo breast-cancer effects were not statistically significant.